Los puntos clave no están disponibles para este artículo en este momento.
Persistence with OAB medications might be improved by addressing predictors of discontinuation in the management of OAB, by proactively informing patients about the severity of antimuscarinic adverse effects, and dosing regimens. Bother associated with the key OAB symptom, urgency, is a predictor of discontinuation of treatment.
Brubaker et al. (Thu,) studied this question.